Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq)
Ontology highlight
ABSTRACT: Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq)
PROVIDER: PRJNA480603 | ENA |
REPOSITORIES: ENA
ACCESS DATA